VERTEX PHARMACEUTICALS INC (VRTX) Forecast, Price Target & Analyst Ratings

NASDAQ:VRTX • US92532F1003

Current stock price

441.03 USD
+5.38 (+1.23%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VERTEX PHARMACEUTICALS INC (VRTX).

Forecast Snapshot

Consensus Price Target

Price Target
$557.95
+ 26.51% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 4, 2026
Period
Q1 / 2026
EPS Estimate
$4.50
Revenue Estimate
3.127B
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$557.95
Upside
+ 26.51%
From current price of $441.03 to mean target of $557.95, Based on 40 analyst forecasts
Low
$333.30
Median
$569.16
High
$673.05

Price Target Revisions

1 Month
3.15%
3 Months
11.36%

Price Target Summary

40 Wall Street analysts provided a forecast for the next 12 months for VRTX. The average price target is 557.95 USD. This implies a price increase of 26.51% is expected in the next year compared to the current price of 441.03.
The average price target has been revised upward by 11.36% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

VRTX Current Analyst RatingVRTX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 5 10 15

Analyst Ratings History

VRTX Historical Analyst RatingsVRTX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 10 20 30 40

Analyst Ratings Consensus

ChartMill Buy Consensus
82.00%
VRTX was analyzed by 40 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about VRTX.
In the previous month the buy percentage consensus was at a similar level.
VRTX was analyzed by 40 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-10Morgan StanleyMaintains Overweight -> Overweight
2026-03-18Maxim GroupUpgrade Hold -> Buy
2026-03-11Truist SecuritiesMaintains Buy -> Buy
2026-03-10OppenheimerMaintains Outperform -> Outperform
2026-03-10B of A SecuritiesMaintains Buy -> Buy
2026-03-10Morgan StanleyMaintains Overweight -> Overweight
2026-03-10CitigroupMaintains Buy -> Buy
2026-03-10JefferiesInitiate Buy
2026-03-10HC Wainwright & Co.Maintains Buy -> Buy
2026-02-17BarclaysMaintains Overweight -> Overweight
2026-02-17Canaccord GenuityMaintains Hold -> Hold
2026-02-17HC Wainwright & Co.Maintains Buy -> Buy
2026-02-13ScotiaBankMaintains Sector Perform -> Sector Perform
2026-02-13OppenheimerUpgrade Perform -> Outperform
2026-02-13RBC CapitalMaintains Outperform -> Outperform
2026-02-13StifelMaintains Hold -> Hold
2026-02-13HC Wainwright & Co.Maintains Buy -> Buy
2026-01-28BarclaysUpgrade Equal-Weight -> Overweight
2026-01-26UBSMaintains Buy -> Buy
2026-01-23Evercore ISI GroupMaintains Outperform -> Outperform
2026-01-22RBC CapitalUpgrade Sector Perform -> Outperform
2026-01-12BernsteinUpgrade Market Perform -> Outperform
2026-01-06Wolfe ResearchUpgrade Peer Perform -> Outperform
2025-12-29Leerink PartnersMaintains Outperform -> Outperform
2025-12-10Wells FargoMaintains Overweight -> Overweight

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 4, 2026
Period
Q1 / 2026
EPS Estimate
$4.50
Revenue Estimate
3.127B
Revenue Q2Q
12.88%
EPS Q2Q
10.87%
Number of Analysts
30

Next Earnings Revisions

Revenue (1 Month)
0.00%
Revenue (3 Months)
-1.73%
EPS (1 Month)
0.76%
EPS (3 Months)
-8.74%

Next Earnings Summary

VRTX is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is 4.5 USD and the consensus revenue estimate is 3.13B USD.
The next earnings revenue estimate has been revised downward by 1.73% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
VRTX revenue by date.VRTX revenue by date.
9.869B
10.51%		11.02B
11.66%		12.001B
8.90%		13.299B
10.81%		14.683B
10.41%		16.477B
12.22%		18.097B
9.83%		19.962B
10.31%		21.175B
6.08%		22.871B
8.01%		24.789B
8.39%
EBITDA
YoY % growth
VRTX ebitda by date.VRTX ebitda by date.
4.54B
-0.96%		4.603B
1.37%		4.895B
6.35%		5.798B
18.44%		6.917B
19.30%		8.1B
17.10%		8.341B
2.98%		9.253B
10.93%		10.116B
9.33%		10.802B
6.78%		12.433B
15.10%
EBIT
YoY % growth
VRTX ebit by date.VRTX ebit by date.
4.359B
-1.73%		4.396B
0.84%		4.685B
6.59%		5.618B
19.91%		6.522B
16.09%		7.526B
15.39%		8.98B
19.32%		10.258B
14.23%		11.409B
11.22%		12.603B
10.47%		14.164B
12.39%
Operating Margin
VRTX operating margin by date.VRTX operating margin by date.
44.17%39.89%39.04%42.24%44.42%45.68%49.62%51.39%53.88%55.10%57.14%
EPS
YoY % growth
VRTX eps by date.VRTX eps by date.
15.22
2.22%		0.29
-98.09%		18.41
6,248.28%		19.48
5.79%		22.31
14.55%		26.05
16.75%		29.24
12.26%		32.97
12.74%		37.19
12.81%		41.27
10.96%		47.06
14.04%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		4.50
10.87%		4.82
6.65%		5.04
5.02%		5.16
2.52%		4.74
5.37%		5.26
9.11%		5.78
14.59%		5.82
12.95%
Revenue
Q2Q % growth		3.127B
12.88%		3.282B
10.70%		3.396B
10.39%		3.509B
10.00%		3.388B
8.35%		3.535B
7.71%		3.702B
9.01%		3.796B
8.18%
EBITDA
Q2Q % growth		1.357B
25.96%		1.455B
16.08%		1.557B
11.63%		1.497B
1.68%		1.562B
15.11%		1.55B
6.53%		1.733B
11.30%		1.91B
27.59%
EBIT
Q2Q % growth		1.276B
24.02%		1.376B
19.31%		1.434B
15.58%		1.461B
15.73%		1.447B
13.40%		1.568B
13.95%		1.737B
21.13%		1.805B
23.55%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

VRTX Yearly Revenue VS EstimatesVRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
VRTX Yearly EPS VS EstimatesVRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30 40

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
12.27%
EPS Next 5 Year
12.36%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
10.47%
Revenue Next 5 Year
10.31%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
14.56%
EBIT Next 5 Year
11.43%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

VERTEX PHARMACEUTICALS INC / VRTX Forecast FAQ

Can you provide the average price target for VERTEX PHARMACEUTICALS INC stock?

40 analysts have analysed VRTX and the average price target is 557.95 USD. This implies a price increase of 26.51% is expected in the next year compared to the current price of 441.03.

What is the next earnings date for VRTX stock?

VERTEX PHARMACEUTICALS INC (VRTX) will report earnings on 2026-05-04.

What are the consensus estimates for VERTEX PHARMACEUTICALS INC (VRTX) next earnings?

The consensus EPS estimate for the next earnings of VERTEX PHARMACEUTICALS INC (VRTX) is 4.5 USD and the consensus revenue estimate is 3.13B USD.

What is the consensus rating for VRTX stock?

The consensus rating for VERTEX PHARMACEUTICALS INC (VRTX) is 82 / 100 . This indicates that analysts generally have a positive outlook on the stock.